Genitourinary Cancers | Specialty

Belzutifan Maintains High, Durable Responses in VHL Disease–Associated Neoplasms At 5 Years

December 5th 2025

At 48 months, the majority of patients with VHL disease–associated tumors remained in response following treatment with belzutifan.

Adjuvant Pembrolizumab Delivers Long-Term Benefits in ccRCC at Increased Risk of Recurrence

December 5th 2025

Adjuvant pembrolizumab delivers sustained clinical benefits across ccRCC subgroups with no new long-term safety signals.

Relief of Venous Congestion May Improve Renal Preservation Despite Worse Baseline Function in RCC With IVC Thrombosis

December 4th 2025

Data from a comparative cohort study suggest that venous congestion is a modifiable driver of renal dysfunction in patients with RCC and IVC thrombosis.

PSMA Theranostics, ctDNA Testing, and Combination Regimens in GU Oncology Spark Conversation at CFS: With Benjamin P. Levy, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

November 13th 2025

Drs Levy and Tagawa discuss the rapidly evolving treatment paradigms for prostate cancer and RCC live at the 43rd Annual Chemotherapy Foundation Symposium.

Immunotherapy Resistance in Kidney Cancer Driven by Myeloid Cell Signaling

November 12th 2025

A study combined single-cell RNA sequencing data from patients with RCC to learn about patterns of interferon signaling across cell types in tumors.

Adjuvant Durvalumab Plus Tremelimumab Yields DFS Advantage in Resected RCC

November 6th 2025

Treatment with adjuvant durvalumab plus tremelimumab resulted in a DFS benefit vs active monitoring in RCC, particularly in the higher-risk population.

Phase 3 KEYNOTE-905 and IMvigor011 Trials Signal New Standards in MIBC

November 6th 2025

Daniel P. Petrylak, MD, discusses key data in MIBC presented during the 2025 ESMO Congress and previews the 19th Annual New York GU Cancers Congress.

Dr Haake on the Rationale for a Tumor Subtype Analysis of Cabozantinib Plus Nivolumab in Metastatic ccRCC

November 5th 2025

The OncFive: Top Oncology Articles for the Week of 10/26

November 1st 2025

Belzutifan-based combinations meet end points in RCC, imaging agent under review for SSTR-positive neuroendocrine tumors, and more.

Dr Sweis on Next Steps for the Investigation of XmAb819 in RCC and Beyond

October 31st 2025

Randy F. Sweis, MD, explains future avenues for the investigation for XmAb819 in tumor types beyond renal cell carcinoma.

Precision Strategies and Targeted Combinations in GU Oncology: Expert Insights From ESMO 2025

October 29th 2025

Experts highlight how precision medicine, biomarkers, and targeted combinations presented at ESMO 2025 are shaping the future of GU cancer treatment.

Belzutifan-Based Combinations Meet DFS, PFS End Points in Renal Cell Carcinoma

October 28th 2025

Two belzutifan-based combinations met their respective primary efficacy end points of DFS and PFS in the phase 3 LITESPARK-022 and LITESPARK-011 trials.

Dr Sweis on the Potential for XmAb819 to Fill Treatment Gaps in Refractory RCC

October 24th 2025

Randy F. Sweis, MD, discusses shares how XmAb819 may address the need for effective therapies after progression on standard regimens in RCC.

Rounding Up Relevant Data in RCC With Drs Beckermann and Rini

October 19th 2025

Brian I. Rini, MD, FASCO, and Katy Beckermann, MD, PhD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in renal cell carcinoma presented during the 2025 ESMO Congress.

Lenvatinib Plus Everolimus Yields PFS Benefit in Previously Treated Advanced Clear Cell RCC

October 18th 2025

Lenvatinib plus everolimus improved PFS vs cabozantinib in metastatic clear cell renal cell carcinoma after progression on a PD-1 inhibitor.

Belzutifan Plus Pembrolizumab and Lenvatinib Demonstrates Potential in Advanced Clear Cell RCC

October 18th 2025

Belzutifan plus pembrolizumab and lenvatinib improved efficacy outcomes compared with multiple other pembrolizumab-based triplet regimens in advanced clear cell renal cell carcinoma.

RNA Sequencing Signatures May Guide Treatment Selection in Advanced ccRCC

October 18th 2025

RNAseq-defined clusters guided treatment selection in metastatic ccRCC in the phase 2 OPTIC trial, yielding a 76% ORR with cabozantinib plus nivolumab.

Fruquintinib Plus Sintilimab Improves PFS in Advanced RCC After First-Line VEGFR TKI Therapy

October 18th 2025

Fruquintinib plus sintilimab significantly extended progression-free survival in advanced RCC following first-line VEGFR TKI therapy.

Dr Sweis on the Expected Safety Profile of XmAb819 in RCC

October 17th 2025

Randy F. Sweis, MD, discusses potential toxicities and mitigation strategies associated with the bispecific T-cell engager XmAb819.

Countdown to ESMO 2025: Catch Up on OncLive’s Extensive Tumor-Specific Previews

October 13th 2025

Preview the top lung, breast, GI, GU, gynecologic, and hematologic oncology abstracts and topics ahead of the 2025 ESMO Congress.